InflaRx N.V.

InflaRx N.V. announced the completion of its underwritten offering, raising aggregate gross proceeds of $150 million. The company sold 75,000,000 ordinary shares at an offering price of $2.00 per share. The net proceeds are intended to advance pipeline activities and for general corporate purposes, with participation from both new and existing investors.

InflaRx N.V. announced the closing of an underwritten public offering of 75,000,000 ordinary shares. The shares were offered at a price of $2.00 per share, resulting in gross proceeds of approximately $150 million before deducting underwriting discounts and estimated offering expenses. The offering was made pursuant to the company's effective shelf registration statement.

InflaRx N.V. announced its intention to develop izicopan, an oral C5a receptor inhibitor, for ANCA-associated vasculitis (AAV) and other life-threatening renal diseases including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G). The company is planning Phase 2 for AAV and open-label studies for other renal indications, with clinical data expected next year. InflaRx estimates it has sufficient funds for planned clinical development and operations through 2029. A Capital Markets Day is scheduled for summer 2026 to detail izicopan's potential.

InflaRx N.V. announced the pricing of an underwritten offering of 75,000,000 ordinary shares at $2.00 per share, totaling $150,000,000 in gross proceeds. The offering, expected to close on May 7, 2026, includes participation from new and existing investors such as TCGX and Farallon Capital Management. The company intends to use the net proceeds to advance its pipeline activities, for working capital, and general corporate purposes.

InflaRx N.V. announced a strategic shift to focus on developing izicopan, an oral C5aR inhibitor, for ANCA-associated vasculitis (AAV) and a broader range of complement-mediated life-threatening kidney diseases, including aHUS, IgAN, and C3G. The company is conducting Phase 2 planning for AAV and expects to begin open-label studies for other renal indications next year. InflaRx also stated it has sufficient funds for planned clinical development activities and ongoing operations through 2029, and will host a Capital Markets Day in summer 2026 to further detail izicopan's potential.

InflaRx N.V. reported a net loss of 5.6 million for Q1 2026, a significant improvement from the 8.3 million loss in Q1 2025. This reduction was driven by a strategic restructuring announced in January 2026, which included a workforce reduction and discontinuation of GOHIBIC (vilobelimab) sales activities in the US. The company is now focusing its resources predominantly on the clinical development of izicopan. Dr. Camilla Chong will also resign as Chief Medical Officer in August 2026.

InflaRx N.V. announced new preclinical data showing izicopan, a next-generation oral C5aR1 inhibitor, has a favorable reactive metabolite profile in human liver microsomes. In a head-to-head in vitro study, izicopan demonstrated minimal reactive metabolite formation, while the comparator avacopan showed significantly higher levels of thiol adducts, consistent with more extensive oxidative bioactivation. These findings support a lower extent of reactive intermediate formation for izicopan, suggesting a differentiated profile within the C5aR inhibitor class with potential safety advantages.

InflaRx N.V. announced new pre-clinical data for its investigational oral C5aR1 inhibitor, izicopan, demonstrating minimal reactive metabolite formation in human liver microsomes. This suggests a lower potential for bioactivation-related safety risks compared to the marketed comparator, avacopan, which showed higher levels of thiol adducts. These findings support izicopan's differentiated profile, building on previous positive Phase 1 and Phase 2a clinical data indicating good tolerability and efficacy in conditions like hidradenitis suppurativa and chronic spontaneous urticaria. The company believes these properties may contribute to its overall differentiation within the C5aR inhibitor class.

InflaRx N.V. (IFRX) announced it will publish its financial and operating results for the first quarter 2026 on May 7, 2026, before the market opens. The biopharmaceutical company, focused on anti-inflammatory therapeutics, also stated that no conference call is planned for this announcement.

InflaRx N.V. announced it has regained compliance with The Nasdaq Stock Market LLC's minimum bid price requirement. The company was previously notified on March 11, 2026, that its ordinary shares were trading below $1.00 for 30 consecutive business days. Nasdaq confirmed on April 27, 2026, that InflaRx's closing bid price was $1.00 or greater for 10 consecutive business days, from April 13 to April 24, 2026, thereby closing the matter.